Pharmafile Logo
Pharmafocus logo
Advanced Search
janssen_latest_logo_on_sign_closer

Janssen to stop fulranumab development in osteoarthritis pain

pharmafile | April 1, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing |  Amgen, Janssen 

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain.

The J&J company says the decision is based on “strategic portfolio prioritisation”, as opposed to concerns over the safety of the drug – which belongs to an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds.

Janssen is terminating its license with Amgen fulranumab and is returning all program rights back to Amgen. The two signed a licensing agreement in 2008.

Advertisement

Joel Levy

Related Content

Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

Amgen opens new biomanufacturing facility in Ohio, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025